Medicinalkoncernen Takeda skal stå for distributionen af Y-mabs to hovedkandidater Danyelza og omburtamab i Israel. Samtidig giver Y-mabs en opdatering på, hvornår omburtamab igen bliver indsendt til godkendelse i USA.
Når det danske, men amerikansk noterede, biotekselskab Y-mabs er klar til at sende sine to lægemidler Danyelza og omburtamab på markedet i Israel, bliver det Takeda, som får ansvaret.
Det oplyser Y-mabs i en pressemeddelelse.
Allerede abonnent? Log Ind.
BRIDGE – Translational Excellence Programme: Call for Outstanding Postdocs and Experienced Mentors interested in Translational Medicine 
Experienced Scientist - LEO Pharma 
Senior Medical Writer - Orphazyme 
Nordic General Director, Pharma - MEDICE 
Er du konsulent med ingeniørbaggrund? - Andreasen & Elmgaard 
QC Manager Drug Substance for Product Supply – Ascendis Pharma 
CMC Project Manager – MC2 Therapeutics 
QC specialist søges - Orifarm 
Erfaren jurist med interesse for lægemiddelområdet - Amgros Artwork Coordinator - Orifarm 
Senior Programming Manager - Genmab QAA Team Manager - Orifarm 
Medicochef til medicoteknologi i største skala - Region Hovedstaden 
Associate Director, GMP QA, Commercial Operations - Y-mAbs Therapeutics Director Pharmacology & New Target Discovery - Y-mAbs 
Director CMC, Drug Substance - Galecto Manager of Medical Writing - Orphazyme 
Scientist Cell Culture - Tech Transfer, Fujifilm Diosynth Biotechnologies Director CMC, Drug Product - Galecto 
Merck – Director Market Access Senior Principal IT Business Partner - Genmab 
Senior Manager Business Development - Ascelia Pharma Senior CMC Specialist, Analytical - Genmab 
Experienced Clinical Project Manager - ALK Senior Manager, Internal Communications - Genmab 
Senior Cost Accountant - Zealand Pharma Senior Accountant - Y-mAbs Therapeutics Supply Chain Manager - Y-mAbs Therapeutics Senior Clinical Trial Manager - Zealand Pharma Senior Scientist, Analytical Development - Zealand Pharma Associate Director Medical Science – Orphazyme Director of Clinical Quality Assurance Operations – Orphazyme Pharmacovigilance Specialist - Orifarm 
Sundhedsfaglig chef - Sano Regulatory Affairs Manager – MC2 Therapeutics 
